Aliases & Classifications for Brain Edema

MalaCards integrated aliases for Brain Edema:

Name: Brain Edema 12 55 44 15 17 72
Intracranial Swelling 12
Cerebral Edema 72
Wet Brain 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4724
MeSH 44 D001929
SNOMED-CT 68 2032001 85974009
UMLS 72 C0006114 C1527311

Summaries for Brain Edema

Disease Ontology : 12 A brain disease that is characterized by excess accumulation of fluid in the intracellular and/or extracellular spaces of the brain, has symptom nausea, has symptom vomiting, has symptom blurred vision, has symptom seizure, has symptom coma.

MalaCards based summary : Brain Edema, also known as intracranial swelling, is related to hydrops, lactic acidosis, and sideroblastic anemia and intracranial hypertension, and has symptoms including vomiting, coma and blurred vision. An important gene associated with Brain Edema is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Pathways in cancer and Selenium Micronutrient Network. The drugs Nicardipine and Tramadol have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and endothelial, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 75 Cerebral edema is excess accumulation of fluid (edema) in the intracellular or extracellular spaces of... more...

Related Diseases for Brain Edema

Diseases related to Brain Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
# Related Disease Score Top Affiliating Genes
1 hydrops, lactic acidosis, and sideroblastic anemia 32.1 VEGFA MIP KNG1 AQP4 ALB
2 intracranial hypertension 31.3 IL1B AQP4 AQP1
3 arteriovenous malformation 30.6 VEGFA MMP9 IL6
4 ischemia 30.4 VEGFA SOD1 KNG1 HMOX1
5 meningitis 30.3 MMP9 IL6 IL1B ALB
6 spinal cord injury 30.3 MMP9 IL6 AQP4
7 bacterial meningitis 30.2 MMP9 IL6 IL1B ALB
8 hepatic encephalopathy 30.1 SLC25A13 SLC1A2 IL6 GLUL ALB
9 peripheral nervous system disease 29.8 IL6 AQP4 ALB
10 proteasome-associated autoinflammatory syndrome 1 29.8 MMP9 IL6 IL1B ALB
11 demyelinating disease 29.5 MMP9 IL1B AQP4
12 pre-eclampsia 29.4 VEGFA KNG1 IL6 HMOX1
13 malaria 28.6 VEGFA MMP9 IL6 IL1B HMOX1 ALB
14 vascular disease 28.0 VEGFA SOD1 MMP9 KNG1 IL6 HMOX1
15 encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 1 12.7
16 encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2 12.6
17 citrullinemia, type ii, adult-onset 11.2
18 encephalopathy, acute, infection-induced 4 11.2
19 mitochondrial complex i deficiency, nuclear type 20 11.0
20 traumatic brain injury 10.7
21 brain injury 10.7
22 cerebral artery occlusion 10.6
23 acute liver failure 10.6
24 severe nonproliferative diabetic retinopathy 10.6 VEGFA ALB
25 encephalopathy 10.5
26 meningioma, radiation-induced 10.5
27 meningioma, familial 10.5
28 spinal meningioma 10.5
29 secretory meningioma 10.5
30 lymphoplasmacyte-rich meningioma 10.5
31 ocular motor apraxia 10.5
32 dysferlinopathy 10.5 MIP AQP4 AQP1
33 intermittent claudication 10.5 VEGFA IL6 ALB
34 obstructive jaundice 10.5 SLC25A13 IL6 ALB
35 hepatic coma 10.4
36 meningitis and encephalitis 10.4 SOD1 ALB
37 meniere disease 10.4 MIP AQP4 AQP1
38 angiokeratoma circumscriptum 10.4 VEGFA MMP9
39 head injury 10.4
40 diabetes insipidus, nephrogenic, autosomal 10.4 MIP AQP4 AQP1
41 recurrent corneal erosion 10.4 IL6 IL1B
42 peripheral vascular disease 10.4 VEGFA IL6 ALB
43 acute transverse myelitis 10.4 MMP9 IL6 AQP4
44 bagassosis 10.4 IL6 IL1B
45 transverse myelitis 10.4 MMP9 IL6 AQP4
46 chronic follicular conjunctivitis 10.4 MMP9 IL1B
47 rosacea 10.4 VEGFA MMP9 IL6
48 glioma 10.4
49 glial tumor 10.4
50 severe pre-eclampsia 10.3 VEGFA MMP9 ALB

Comorbidity relations with Brain Edema via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Cancer
Brain Compression Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Hypertension, Essential

Graphical network of the top 20 diseases related to Brain Edema:



Diseases related to Brain Edema

Symptoms & Phenotypes for Brain Edema

Symptoms:

12
  • vomiting
  • coma
  • blurred vision
  • nausea
  • seizure

UMLS symptoms related to Brain Edema:


edema, headache, peau d'orange

MGI Mouse Phenotypes related to Brain Edema:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 AQP1 AQP4 BDKRB2 GLUL HMOX1 IL6
2 growth/size/body region MP:0005378 10.34 ANXA1 AQP1 AQP4 GLUL HMOX1 IL1B
3 homeostasis/metabolism MP:0005376 10.33 ALB ANXA1 AQP1 AQP4 BDKRB2 GLUL
4 cellular MP:0005384 10.28 ALB ANXA1 BDKRB2 GLUL HMOX1 IL6
5 cardiovascular system MP:0005385 10.25 ANXA1 AQP1 AQP4 BDKRB2 HMOX1 IL1B
6 mortality/aging MP:0010768 10.24 ALB ANXA1 AQP1 AQP4 BDKRB2 GLUL
7 hematopoietic system MP:0005397 10.22 ANXA1 AQP1 AQP4 BDKRB2 HMOX1 IL1B
8 endocrine/exocrine gland MP:0005379 10.21 ALB ANXA1 AQP1 AQP4 BDKRB2 HMOX1
9 immune system MP:0005387 10.13 ANXA1 AQP4 BDKRB2 HMOX1 IL1B IL6
10 digestive/alimentary MP:0005381 10.07 ALB ANXA1 AQP4 BDKRB2 IL6 MMP9
11 nervous system MP:0003631 10.03 ANXA1 AQP1 AQP4 GLUL IL1B IL6
12 liver/biliary system MP:0005370 10.01 ALB GLUL HMOX1 IL6 OTC SLC25A13
13 neoplasm MP:0002006 9.87 ALB ANXA1 IL1B IL6 MMP9 SOD1
14 renal/urinary system MP:0005367 9.85 ALB AQP1 AQP4 BDKRB2 HMOX1 IL6
15 reproductive system MP:0005389 9.56 AQP1 BDKRB2 HMOX1 IL6 MMP9 OTC
16 skeleton MP:0005390 9.23 ANXA1 AQP1 BDKRB2 IL1B IL6 MMP9

Drugs & Therapeutics for Brain Edema

DrugBank drugs 16 :

(show all 7)
# Drug Name Indication DrugBank ID
1 Betamethasone DB00443
2 Bupivacaine For the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures. DB00297
3 Dexamethasone <B>Injection:</B> for the treatment of endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema. <br><B>Ophthalmic ointment and solution:</B> for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. <br><B>Ophthalmic solution only:</B> for the treatment of steroid responsive inflammatory conditions of the external auditory meatus <br><B>Topic cream:</B> for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses <br><B>Oral aerosol:</B> for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy <br><B>Intranasal aerosol:</B> for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps DB01234
4 Mannitol Used for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances. DB00742
5 Prednisolone For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders. DB00860
6 Prednisone For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis. DB00635
7 Triamcinolone For the treatment of perennial and seasonal allergic rhinitis. DB00620

Drugs for Brain Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 230)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
2
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
3
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
4
Conivaptan Approved, Investigational Phase 4 210101-16-9 151171
5 Vasodilator Agents Phase 4
6 Narcotics Phase 4
7 Analgesics, Opioid Phase 4
8 Progestins Phase 4
9 Pharmaceutical Solutions Phase 4
10 Antidiuretic Hormone Receptor Antagonists Phase 4
11 Arginine Vasopressin Phase 4
12 Vasopressins Phase 4
13
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
14
Misoprostol Approved Phase 3 59122-46-2 5282381
15
Oxytocin Approved, Vet_approved Phase 3 50-56-6 439302 53477758
16
Carbetocin Approved, Investigational Phase 3 37025-55-1 16681432 71715
17
Glyburide Approved Phase 3 10238-21-8 3488
18
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
19
Artesunate Approved, Investigational Phase 3 88495-63-0 5464098 6917864
20
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
21
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 54670067 5785
22 Tocotrienol Investigational Phase 3 6829-55-6
23 3-n-butylphthalide Phase 3
24 Platelet Aggregation Inhibitors Phase 3
25 Tocotrienols Phase 3
26 Tocopherols Phase 3
27 Alpha-lipoic Acid Phase 3
28 Thioctic Acid Phase 3
29 Antacids Phase 3
30 Anti-Ulcer Agents Phase 3
31 Oxytocics Phase 3
32 Hypoglycemic Agents Phase 3
33 Analgesics, Non-Narcotic Phase 2, Phase 3
34 Tissue Plasminogen Activator Phase 2, Phase 3
35 Adrenergic alpha-2 Receptor Agonists Phase 2, Phase 3
36 Hypnotics and Sedatives Phase 2, Phase 3
37 Anesthetics, General Phase 2, Phase 3
38 Anesthetics, Intravenous Phase 2, Phase 3
39 Artemisinins Phase 3
40 Artemisinine Phase 3
41 Cardiotonic Agents Phase 3
42 Protective Agents Phase 3
43 Neuroprotective Agents Phase 3
44 Cardiac Glycosides Phase 3
45
leucovorin Approved Phase 2 58-05-9 143 6006
46
Ibuprofen Approved Phase 2 15687-27-1 3672
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
49
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
50
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
2 An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage Unknown status NCT00325793 Phase 4 Nicardipine
3 Correlation of Measured and Calculated Serum Osmolality During Mannitol or Hypertonic Saline Infusion in Patients After Craniotomy Completed NCT02037815 Phase 4 20% mannitol solution, 125 ml, IV infusion in 15 min;3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
4 Micronized Oral Progesterone and Effect on Time Symptomatic From Concussion: A Pilot Study Completed NCT01809639 Phase 4 Progesterone;Placebo
5 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing Completed NCT01993667 Phase 4 Low Dose Acetazolamide;Normal Dose Acetazolamide
6 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
7 Randomized Controlled Trial of Intravenous Fluid In Severely Injured Paediatric Trauma Patients: Comparison of Normal Saline Versus Ringer's Lactate Completed NCT01692769 Phase 4 Normal Saline;Ringer's Lactate
8 Effect of Isosmotic Doses of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation in Supratentorial Craniotomies Recruiting NCT03573999 Phase 4 Mannitol;NaCl 7.5%
9 A Single-center Randomized Double Blinded Control Trial of Intravenous Fluid Content in Children With Diabetic Ketoacidosis Admitted to the Pediatric Intensive Care Unit Recruiting NCT03066440 Phase 4 Normal saline;Lactated Ringers
10 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
11 Effect of Clevidipine on Intracranial Pressure, Cerebral Blood Flow, Brain Tissue Oxygenation and Brain Cellular Metabolism in Severely Hypertensive Patients With Acute Brain Injury Withdrawn NCT01526876 Phase 4 clevidipine butyrate
12 Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis Completed NCT01365793 Phase 3 0.45% saline replacement fluid;0.9% saline replacement fluid;0.45% saline intravenous fluid;0.9% saline Intravenous fluid
13 An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
14 A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone Completed NCT00088166 Phase 3 hCRF;placebo hCRF
15 Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting Completed NCT01405248 Phase 3 Butylphthalide;Placebo
16 Fluid Shift in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest, and How do They Manage Life Afterwards? Completed NCT00347477 Phase 3 HyperHAES vs. RA-solution/NaCl
17 Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial Completed NCT01556646 Phase 3 Tolvaptan
18 Randomized Double-Blind Placebo-Controlled Trial of Oral Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness. Completed NCT00664001 Phase 3
19 Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia. Completed NCT02086994 Phase 3 misoprostol;carbetocin
20 Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring Completed NCT01591018 Phase 3
21 Risk Reduction of Symptomatic and Silent Brain Infarctions During Carotid Endarterectomy and Carotid Stenting Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring Completed NCT01591005 Phase 3
22 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction Recruiting NCT02864953 Phase 3 BIIB093;Placebo
23 Salovum (Antisecretory Factor) in Patients With Severe Traumatic Brain Injury Recruiting NCT03339505 Phase 3
24 Safety and Efficacy of Glibenclamide Combined With Rt-PA in Treating Acute Ischemic Stroke: a Prospective, Randomized, Double-blind, Placebo-control, Multi-center Study Recruiting NCT03284463 Phase 2, Phase 3 Glibenclamide;Placebo
25 Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients With and Without Traumatic Brain Injury. Recruiting NCT03285165 Phase 2, Phase 3 0.2-0.7 mcg/kg/h dexmedetomedine infusion.;10-70 mcg/kg/h propofol infusion.
26 Treating Brain Swelling in Pediatric Cerebral Malaria Recruiting NCT03300648 Phase 3
27 Efficacy and Safety of Neuroprotectant Cattle Encephalon Glycoside and Ignotin Injection for Intracerebral Hemorrhage: a Multicenter, Randomized, Double-blinded, Placebo-controlled Trial. Not yet recruiting NCT03546283 Phase 3 Placebos;Cattle Encephalon Glycoside and Ignotin
28 Decompressive Craniectomy In Malignant Middle Cerebral Artery Infarcts : A Sequential Design, Multicenter, Randomized, Controlled Trial Terminated NCT00190203 Phase 3
29 A Phase III Randomized, Double-Blind Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Dexamethasone for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Primary Malignant Glioma Withdrawn NCT00226668 Phase 3 hCRF;placebo hCRF
30 Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET) Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
31 Evaluation and Correlation Between the Disruption in Blood-brain-barrier and the Development of Secondary Brain Edema Associated With Brain Damage by Using MRI in Patients With Various Types of Intra-cranial Bleeding Unknown status NCT01830894 Phase 1, Phase 2
32 Safety and Tolerability of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage Unknown status NCT01866384 Phase 2
33 Prospective, Double-blind, Randomized, Placebo-controlled Trial of Ibuprofen Versus Placebo for Prevention of Neurologic Forms of Altitude Sickness Unknown status NCT01606527 Phase 2 Ibuprofen 600mg orally three times daily
34 High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma – a Phase II Study Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
35 Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury Unknown status NCT02443142 Phase 2 Ibuprofen;Acetaminophen
36 Intraosseous Administration of Hypertonic Saline in Acute Brain-injured Patients: A Prospective Case Series and Literature Review Completed NCT03276494 Phase 2 Hypertonic saline
37 Comparison of Balanced Crystalloid Solution and 0,9% Sodium Chloride in Children Undergoing Brain Tumor Resection: a Randomized Controlled Trial Completed NCT02707549 Phase 2 balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride);0.9% sodium chloride
38 Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke Completed NCT01428401 Phase 2 Chinese Herb Astragalus membranaceus
39 Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator Completed NCT00777140 Phase 2 Deferoxamine
40 A Modified Phase I/II Trial Of Rapamycin In Patients With Glioblastoma Multiforme Completed NCT00047073 Phase 1, Phase 2 Rapamycin
41 Glutaminergic and Histaminergic Pathway Modulation in Acute Ischemic Stroke as an Effective Neuroprotection Strategy. Completed NCT02142712 Phase 2 Diphenhydramine;Pantoprazole;Famotidine;Dextromethorphan
42 Hypothermia Treatment in Hyperammonemia and Encephalopathy Completed NCT01624311 Phase 2
43 A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury Completed NCT01548690 Phase 2 Ornithine Phenylacetate
44 PET Imaging of Translocator Protein in Subjects With Traumatic Brain Injury Completed NCT01547780 Phase 1, Phase 2
45 A Phase II Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma Completed NCT02157103 Phase 2 Bevacizumab 25 mg in 1 ml subcutaneously daily
46 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
47 A Pilot Study and Phase II Double Blind Placebo Controlled Randomized Trial Examining the Safety and Efficacy of Glyburide as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases Recruiting NCT02460874 Phase 1, Phase 2 Glyburide
48 The Effect of Thalidomide in Radiation-induced Brain Injury(RI): a Phase II Clinical Trial Recruiting NCT03208413 Phase 2 Thalidomide
49 A Double-blind, Randomized and Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent Active, not recruiting NCT03621410 Phase 2 T89 225 mg group;Placebo;T89 300 mg group
50 A Prospective, Multicenter, Randomized Controlled Trial of Apatinib Combined With Radiotherapy in Patient With Brain Metastases From Drive Gene Negative NSCLC Not yet recruiting NCT03801200 Phase 2 Apatinib

Search NIH Clinical Center for Brain Edema

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Betamethasone
Bupivacaine
Dexamethasone
Dexamethasone
dexamethasone acetate
DEXAMETHASONE ACETATE PWDR
Dexamethasone phosphate
Dexamethasone sodium phosphate
DEXAMETHASONE SODIUM PHOSPHATE PWDR
Mannitol
Mannitol
Mannitol hexanitrate
MANNITOL PWDR
Prednisolone
Prednisone
Triamcinolone

Cochrane evidence based reviews: brain edema

Genetic Tests for Brain Edema

Anatomical Context for Brain Edema

MalaCards organs/tissues related to Brain Edema:

41
Brain, Liver, Endothelial, Cortex, Lung, Bone, Neutrophil

Publications for Brain Edema

Articles related to Brain Edema:

(show top 50) (show all 6432)
# Title Authors PMID Year
1
Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. 9 38
20168229 2010
2
Aquaporin-4 and traumatic brain edema. 9 38
20356447 2010
3
Ammonia and proinflammatory cytokines modify expression of genes coding for astrocytic proteins implicated in brain edema in acute liver failure. 9 38
20217200 2010
4
[Regulation, structure and function of brain aquaporin]. 9 38
20030210 2009
5
[AQP4 expression in the brains of patients with glioblastoma and its association with brain edema]. 9 38
19764565 2009
6
Roles of aquaporin-4 isoforms and amino acids in square array assembly. 9 38
19445480 2009
7
Role of bradykinin and catecholamines in cerebral infarction and brain edema. 9 38
19265042 2009
8
Acetazolamide reversibly inhibits water conduction by aquaporin-4. 9 38
19114109 2009
9
Hypoxia-inducible factor-1alpha signaling in aquaporin upregulation after traumatic brain injury. 9 38
19429018 2009
10
Actin cytoskeleton remodeling governs aquaporin-4 localization in astrocytes. 9 38
18649401 2008
11
[The relationship between the aquaporin-4 and brain edema, pathologic change, ultrastructure in peri-hematoma tissue in patients with intracerebral hemorrhage]. 9 38
19000426 2008
12
Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides. 9 38
18572411 2008
13
The expression and the role of protease nexin-1 on brain edema after intracerebral hemorrhage. 9 38
18442833 2008
14
High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA. 9 38
18436890 2008
15
The role of aquaporin-4 polymorphisms in the development of brain edema after middle cerebral artery occlusion. 9 38
18309154 2008
16
Aquaporin-4 in hepatic encephalopathy. 9 38
17879149 2007
17
Aquaporins: multiple roles in the central nervous system. 9 38
17901256 2007
18
Can variation in aquaporin 4 gene be associated with different outcomes in traumatic brain edema? 9 38
17890008 2007
19
Temporal and regional evolution of aquaporin-4 expression and magnetic resonance imaging in a rat pup model of neonatal stroke. 9 38
17622964 2007
20
Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. 9 38
17335082 2007
21
Aquaporin 4 regulation during acute and long-term experimental Herpes simplex virus encephalitis. 9 38
17454447 2007
22
Aquaporins as targets for drug discovery. 9 38
17692010 2007
23
Control of brain glutamine synthesis by NMDA receptors. 9 38
17127345 2007
24
[Personal recollection of episodes devoted to my study of neuropathology]. 9 38
17432177 2006
25
Astrocyte end-feet in germinal matrix, cerebral cortex, and white matter in developing infants. 9 38
16627880 2006
26
Astrocytes co-express aquaporin-1, -4, and vascular endothelial growth factor in brain edema tissue associated with brain contusion. 9 38
16671493 2006
27
Sulforaphane enhances aquaporin-4 expression and decreases cerebral edema following traumatic brain injury. 9 38
16211562 2005
28
[Brain edema and aquaporin]. 9 38
16313100 2005
29
Enhanced expression of aquaporin 4 in human brain with inflammatory diseases. 9 38
16133546 2005
30
Endothelin-1 overexpression leads to further water accumulation and brain edema after middle cerebral artery occlusion via aquaporin 4 expression in astrocytic end-feet. 9 38
15815585 2005
31
[Protective effects of total paeony glycoside against global cerebral ischemia-reperfusion injury in gerbils]. 9 38
15837661 2005
32
Blood-brain barrier disruption highly induces aquaporin-4 mRNA and protein in perivascular and parenchymal astrocytes: protective effect by estradiol treatment in ovariectomized animals. 9 38
15772982 2005
33
Risk of worsened encephalopathy after intravenous glycerol therapy in patients with adult-onset type II citrullinemia (CTLN2). 9 38
15805705 2005
34
In vivo expression of aquaporin-4 by reactive microglia. 9 38
15525343 2004
35
Molecular mechanisms and drug development in aquaporin water channel diseases: structure and function of aquaporins. 9 38
15557734 2004
36
Aquaporin water channels in central nervous system. 9 38
16181079 2004
37
Aquaporins and brain edema. 9 38
15120208 2004
38
Alpha-syntrophin deletion removes the perivascular but not endothelial pool of aquaporin-4 at the blood-brain barrier and delays the development of brain edema in an experimental model of acute hyponatremia. 9 38
14734638 2004
39
Regulation of brain aquaporins. 9 38
15561410 2004
40
Importance of aquaporins in the physiopathology of brain edema. 9 38
15281891 2004
41
Aquaporin water channels: molecular mechanisms for human diseases. 9 38
14630322 2003
42
Enhanced expression of aquaporin 4 in human brain with infarction. 9 38
12715185 2003
43
Inhibition of aquaporin-4 expression in astrocytes by RNAi determines alteration in cell morphology, growth, and water transport and induces changes in ischemia-related genes. 9 38
12824287 2003
44
Testosterone up-regulates aquaporin-4 expression in cultured astrocytes. 9 38
12774311 2003
45
[Relationship between aquaporin-4 expression in astrocytes and brain edema caused by glioma]. 9 38
12810377 2003
46
Pathophysiology of traumatic brain edema: current concepts. 9 38
14753394 2003
47
Therapeutical efficacy of a novel non-peptide bradykinin B2 receptor antagonist on brain edema formation and ischemic tissue damage in focal cerebral ischemia. 9 38
14753436 2003
48
Bench to bedside: brain edema and cerebral resuscitation: the present and future. 9 38
12208684 2002
49
Aquaporins in the central nervous system. 9 38
11115728 2001
50
Lipocortin-1 fails to ameliorate cold-injury brain edema in the rat. 9 38
11450032 2000

Variations for Brain Edema

Expression for Brain Edema

Search GEO for disease gene expression data for Brain Edema.

Pathways for Brain Edema

Pathways related to Brain Edema according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1 12.67 VEGFA MMP9 IL6 HMOX1 BDKRB2
2
Show member pathways
12.15 SOD1 IL6 IL1B ALB
3 11.99 VEGFA IL6 IL1B AQP4
4 11.9 VEGFA MMP9 IL1B HMOX1
5 11.81 MMP9 IL6 IL1B
6 11.79 VEGFA IL6 HMOX1
7 11.74 VEGFA IL6 IL1B
8
Show member pathways
11.72 SOD1 MMP9 IL6 IL1B
9 11.7 VEGFA IL6 IL1B
10 11.56 MMP9 IL6 IL1B
11 11.51 MMP9 IL6 IL1B AQP4 AQP1 ANXA1
12
Show member pathways
11.36 VEGFA MMP9 IL6 IL1B
13 11.35 MMP9 KNG1 IL6
14 11.26 MMP9 IL6 IL1B HMOX1
15 11.16 VEGFA MMP9 IL6 IL1B HMOX1 ANXA1
16 11.15 SOD1 IL6 IL1B
17 11.12 IL6 IL1B HMOX1
18 11.08 MMP9 IL6 HMOX1
19
Show member pathways
10.43 SLC1A2 GLUL

GO Terms for Brain Edema

Cellular components related to Brain Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 VEGFA SOD1 NAXE MMP9 KNG1 IL6
2 extracellular exosome GO:0070062 9.61 SOD1 NAXE MMP9 KNG1 IL1B GLUL
3 secretory granule GO:0030141 9.5 VEGFA SOD1 IL1B
4 platelet alpha granule lumen GO:0031093 9.43 VEGFA KNG1 ALB
5 extracellular space GO:0005615 9.32 VEGFA SOD1 NAXE MMP9 KNG1 IL6

Biological processes related to Brain Edema according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.97 SLC25A13 SLC1A2 MIP AQP4 AQP1
2 inflammatory response GO:0006954 9.89 KNG1 IL6 IL1B BDKRB2 ANXA1
3 positive regulation of angiogenesis GO:0045766 9.76 VEGFA IL1B HMOX1 AQP1
4 positive regulation of apoptotic process GO:0043065 9.73 SOD1 MMP9 KNG1 IL6 HMOX1 ANXA1
5 positive regulation of T cell proliferation GO:0042102 9.71 IL6 IL1B ANXA1
6 cellular response to hydrogen peroxide GO:0070301 9.7 IL6 AQP1 ANXA1
7 negative regulation of apoptotic process GO:0043066 9.7 VEGFA SOD1 MMP9 IL6 AQP1 ANXA1
8 platelet degranulation GO:0002576 9.67 VEGFA SOD1 KNG1 ALB
9 embryo implantation GO:0007566 9.65 SOD1 MMP9 IL1B
10 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.61 VEGFA HMOX1 ANXA1
11 positive regulation of glial cell proliferation GO:0060252 9.6 IL6 IL1B
12 macrophage differentiation GO:0030225 9.59 VEGFA MMP9
13 L-glutamate transmembrane transport GO:0015813 9.58 SLC25A13 SLC1A2
14 cellular response to cadmium ion GO:0071276 9.58 SOD1 MMP9 HMOX1
15 multicellular organismal water homeostasis GO:0050891 9.57 AQP4 AQP1
16 positive regulation of chemokine biosynthetic process GO:0045080 9.56 IL1B HMOX1
17 response to glucocorticoid GO:0051384 9.55 IL6 ANXA1
18 positive regulation of neuroinflammatory response GO:0150078 9.51 IL6 IL1B
19 water transport GO:0006833 9.5 MIP AQP4 AQP1
20 response to drug GO:0042493 9.35 SOD1 SLC1A2 OTC AQP1 ANXA1
21 cytokine-mediated signaling pathway GO:0019221 9.1 VEGFA MMP9 IL6 IL1B HMOX1 ANXA1

Molecular functions related to Brain Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 VEGFA SOD1 SLC25A13 MMP9 GLUL AQP1
2 L-glutamate transmembrane transporter activity GO:0005313 9.32 SLC25A13 SLC1A2
3 channel activity GO:0015267 9.13 MIP AQP4 AQP1
4 water transmembrane transporter activity GO:0005372 8.96 AQP1
5 water channel activity GO:0015250 8.8 MIP AQP4 AQP1

Sources for Brain Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....